Higher US generic drugs user fee for foreign units 'discriminatory, anti-competitive', say Indian firms
This article was originally published in SRA
Executive Summary
Indian firms believe that the US Food and Drug Administration's proposed generic drug user fee plan, under which foreign facilities will be required to pay more for inspections, is discriminatory and unwarranted1.